Since IL-8 treatment induces myotube atrophy via the receptor CXCR2, we next aimed to determine the extent to which the CXCR2 antagonist, SB225002, could attenuate human pancreatic cancer cell CM-induced atrophy. Here, CXCR2 is linked to familial pancreatic carcinoma.